| Autor: |
Muh Akbar Bahar, Ikhwan Yuda Kusuma, Ádám Visnyovszki, Mária Matuz, Ria Benkő, Tamás Ferenci, Bálint Gergely Szabó, Edit Hajdú, Zoltán Pető, Dezső Csupor |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Heliyon, Vol 10, Iss 9, Pp e29808- (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2405-8440 |
| DOI: |
10.1016/j.heliyon.2024.e29808 |
| Popis: |
Purpose: Favipiravir has been used in the therapy of COVID-19, including patients with mild to moderate symptoms in certain countries. The aim of our systematic review and meta-analysis was to investigate its efficacy and safety in mild-to-moderate COVID-19 infections. Methods: The PubMed, Embase, Web of Science, and Cochrane databases were systematically reviewed for articles reporting the results of randomized controlled trials published until January 6, 2023, resulting in the identification of 20 eligible studies. Results: There were no significant differences in viral clearance time (HR = 1.20, p = 0.09) compared to those without favipiravir therapy. However, in the subgroup analyses, favipiravir treatment significantly increased viral clearance by 59 % (HR = 1.59, p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
